DNAprint Genomics (DNAG)

[stakddek]

Face recognition: Seven Degrees of separation?

++++++++++++++++++++++

http://biz.yahoo.com/bw/050711/115494.html?.v=1


++++++++++++++++++++++
IRIS International Listed on Russell Indices
Monday July 11, 8:41 am ET


CHATSWORTH, Calif.--(BUSINESS WIRE)--July 11, 2005--IRIS International, Inc. (NASDAQ: IRIS - News), a manufacturer and marketer of automated IVD urinalysis systems and medical devices used in hospitals and reference clinical laboratories worldwide, today announced that it has been listed on the new Russell Microcap(TM) Index as well as the small-cap Russell 2000® and broad market Russell 3000® indices.
ADVERTISEMENT


The listings are the result of Russell's reconstitution of its family of U.S. indices on June 24. IRIS' membership in the Russell 3000, which remains in place for one year, means automatic inclusion in the Russell 2000. Russell's transparent, objective approach in the reconstitution process is based on weighted market capitalization.

"We are pleased that IRIS' stock has qualified for inclusion in the new Russell Microcap Index and the Russell 2000 and 3000, which will further increase IRIS' visibility with institutional managers and investors," stated President and Chief Executive Officer Cesar Garcia

The Russell Microcap Index is comprised of the smallest 1,000 securities in the small-cap Russell 2000 Index plus the next 1,000 companies, based on a ranking of all U.S. equities by market capitalization. This new index offers managers and other investors a comprehensive, unbiased barometer to compare their performance against the genuine microcap marketplace of stocks. The end result is a group of indexes widely used as benchmarks by investment managers and institutional investors in the development of their investment strategies. Investment managers who oversee these funds, purchase shares of members stocks according to that company's weighting in the particular index. Currently, more than $2.5 trillion in assets are benchmarked to Russell indices.

About Russell

Russell, a global leader in multi-manager investment services, provides investment products and services in more than 39 countries. Russell manages more than $135 billion in assets and advises clients worldwide representing $2.3 trillion. Founded in 1936, Russell is a subsidiary of Northwestern Mutual and is headquartered in Tacoma, Wash., with additional offices in New York, Toronto, London, Paris, Singapore, Sydney, Auckland and Tokyo.

THE COMPANY

IRIS International, Inc. (www.proiris.com) is a leader in automated urinalysis technology with systems in major medical institutions throughout the world. The Company's newest generation iQ®200 Automated Urine Microscopy Analyzer, utilizing image flow cytometry, patented Automated Intelligent Microscopy (AIM) technology and neural network-based particle recognition, achieves a significant reduction in the cost and time-consuming steps involved in manual microscopic analysis. The Company's StatSpin® subsidiary, based in Norwood, Mass., manufactures innovative centrifuges and blood analysis products. Advanced Digital Imaging Research, LLC (ADIR), based near Houston, Texas, is the Company's imaging research and development subsidiary.

SAFE HARBOR PROVISION

This news release contains forward-looking statements made in reliance upon the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, the Company's views on future commercial revenues, market growth, capital requirements, and new product introductions, and are generally identified by phrases such as "thinks," "anticipates," "believes," "estimates," "expects," "intends," "plans," and similar words. Forward-looking statements are not guarantees of future performance and are inherently subject to uncertainties and other factors which could cause actual results to differ materially from the forward-looking statement. These statements are based upon, among other things, assumptions made by, and information currently available to, management, including management's own knowledge and assessment of the Company's industry, competition and capital requirements. Other factors and uncertainties that could affect the Company's forward-looking statements include, among other things, the following: the acceptance by customers of our new iQ®200 product platform, our substantial expansion of international sales and our reliance on key suppliers, the potential need for changes in long-term strategy in response to future developments; future advances in diagnostic testing methods and procedures, as well as potential changes in government regulations and healthcare policies, both of which could adversely affect the economics of the diagnostic testing procedures automated by the Company's products; rapid technological change in the microelectronics and software industries; and increasing competition from imaging and non-imaging based in-vitro diagnostic products. The Company refers interested persons to its most recent Annual Report on Form 10-K and its other SEC filings for a description of additional uncertainties and factors that may affect forward-looking statements. The Company assumes no duty to update its forward-looking statements.



--------------------------------------------------------------------------------
Contact:
IRIS International, Inc.
Cesar Garcia, 818-709-1244 Ext. 123
or
The Wall Street Group, Inc.
Ron Stabiner, 212-888-4848



--------------------------------------------------------------------------------
Source: IRIS International, Inc.


++++++++++++++++++++++

Stakddek